Login
E-mail
Password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

I Leader della Finanza

Ultime notizieSocietÓMercatiEconomia & ForexMaterie PrimeTassiLeader della FinanzaPro. della FinanzaAgendaSettori 
HomeTutte le notizieLe notizie pi¨ letteBiografie dei Leader della finanza
Portrait de David T. Scadden
EtÓ : 67
Patrimonio pubblico : 2 536 585 USD
Principali societÓ : Agios Pharmaceuticals, Inc. - Editas Medicine, Inc. - Magenta Therapeutics, Inc.
Riassunto 
David T. Scadden is an entrepreneur who founded 6 companies, among them: Fate Therapeutics, Inc., Magenta Therapeutics, Inc. and Massachusetts General Hospital Cancer Center.

He is Chairman-Emeritus & Professor at Harvard University, Director-Regenerative Medicine Center at The General Hospital Corp. (he founded the company), Associate Member at Massachusetts Institute of Technology, Member of American Academy of Arts & Sciences, Member of Institute of Medicine, Associate Member at The Broad Institute, Inc., Chairman-Emeritus & Professor at Harvard Medical School, Fellow at American College of Physicians and Member of National Academy of Medicine of United States and on the board of 7 other companies.

David T. Scadden previously was Director-Hematologic Malignancies Center at Massachusetts General Hospital Cancer Center (he founded the company in 2003), Member-External Experts Board at National Heart, Lung & Blood Institute and Member-Scientific Counselors Board at National Cancer Institute.

David T. Scadden received an undergraduate degree from Bucknell University, a graduate degree from Case Western Reserve University and a doctorate from the University of Lund.


Posti e reponsabilitÓ di David T. Scadden 
NomeTitolo Da
Agios Pharmaceuticals, Inc.
(Biotecnologia)
Independent Director 2017
Editas Medicine, Inc.
(Biotecnologia)
Independent Director 2019
Magenta Therapeutics, Inc.
(Biotecnologia)
Independent Director 2016
Harvard University Chairman-Emeritus & Professor 2006
Harvard Medical School Chairman-Emeritus & Professor -
Harvard Stem Cell Institute Director 2004
Red Oak Medicines, Inc. Director -
Clear Creek Bio, Inc. Director -
Lifevault Bio Director -
The General Hospital Corp. Director-Regenerative Medicine Center -
Massachusetts Institute of Technology Associate Member -
American Academy of Arts & Sciences Member -
Institute of Medicine Member -
The Broad Institute, Inc. Associate Member -
American College of Physicians Fellow -
National Academy of Medicine of United States Member -


Participazioni di David T. Scadden 
NomeAzioni%Valorizzazione
Magenta Therapeutics, Inc. (MGTA)
(Biotecnologia)
228 1750,39%2 231 552 USD
Agios Pharmaceuticals, Inc. (AGIO)
(Biotecnologia)
5 5350,0090%305 034 USD
Editas Medicine, Inc. (EDIT)
(Biotecnologia)
00,0000%0 USD


David T. Scadden: network personale 
Le notizie pi¨ lette 
21/07CARLOS TAVARES: Stellantis, carenza globale chip proseguirà nel 2022 - Tavares (Ceo)
RE
16/07JOHN ELKANN: Elkann corteggia Armani per polo del lusso - fonti
RE
13/07BRUNELLO CUCINELLI: Brunello Cucinelli migliora ancora l'outlook sul 2021
RE
22/07PHILIPPE DONNET: Generali, grandi soci privati potrebbero chiedere a Donnet di non presentare piano - stampa
RE
21/07FRANCESCO GAETANO CALTAGIRONE: Mediobanca, Caltagirone detiene 3,003% al 20 luglio - Consob
RE
16/07ANDREA ORCEL: Italia avrà sempre ruolo centrale per la banca - stampa
RE
14/07FRANCESCO STARACE: Enel sostiene fermamente pacchetto Ue su clima - Starace
RE
15/07ANDREA ORCEL: Unicredit, Orcel prosegue semplificazione struttura
RE
14/07BRUNELLO CUCINELLI: Cucinelli, holding avvia cessione 0,95% capitale via ABB, ribadisce impegno famiglia
RE
14/07ANDREA ORCEL: M&A non prioritario, nuove condizioni per Mps - Messaggero
RE
Pi¨ notizie


© 2021 People and Ownership :   
David T. Scadden : connessioni